Student or educator? Sign up with your school email and get 6 months of Pro free.

The DOI matches its Crossref record; 29 of the 29 references it cites were found in a registry or an index.

Maternal immunisation with trivalent inactivated influenza vaccine for prevention of influenza in infants in Mali: a prospective, active-controlled, observer-blind, randomised phase 4 trial

Open access

Abstract

BACKGROUND: Despite the heightened risk of serious influenza during infancy, vaccination is not recommended in infants younger than 6 months. We aimed to assess the safety, immunogenicity, and efficacy of maternal immunisation with trivalent inactivated influenza vaccine for protection of infants against a first episode of laboratory-confirmed influenza. METHODS: We did this prospective, active-controlled, observer-blind, randomised phase 4 trial at six referral centres and community health centres in Bamako, Mali. Third-trimester pregnant women (≥28 weeks' gestation) were randomly assigned (1:1), via a computer-generated, centre-specific list with alternate block sizes of six or 12, to receive either trivalent inactivated influenza vaccine or quadrivalent meningococcal vaccine. Study personnel administering vaccines were not masked to treatment allocation, but allocation was concealed from clinicians, laboratory personnel, and participants. Infants were visited weekly until age 6 months to detect influenza-like illness; laboratory-confirmed influenza diagnosed with RT-PCR. We assessed two coprimary objectives: vaccine efficacy against laboratory-confirmed influenza in infants born to women immunised any time prepartum (intention-to-treat population), and vaccine efficacy in infants born to women immunised at least 14 days prepartum (per-protocol population). The primary outcome was the occurrence of a first case of laboratory-confirmed influenza by age 6 months. This trial is registered with ClinicalTrials.gov, number NCT01430689. FINDINGS: We did this trial from Sept 12, 2011, to Jan 28, 2014. Between Sept 12, 2011, and April 18, 2013, we randomly assigned 4193 women to receive trivalent inactivated influenza vaccine (n=2108) or quadrivalent meningococcal vaccine (n=2085). There were 4105 livebirths; 1797 (87%) of 2064 infants in the trivalent inactivated influenza vaccine group and 1793 (88%) of 2041 infants in the quadrivalent meningococcal vaccine group were followed up until age 6 months. We recorded 5279 influenza-like illness episodes in 2789 (68%) infants, of which 131 (2%) episodes were laboratory-confirmed influenza. 129 (98%) cases of laboratory-confirmed influenza were first episodes (n=77 in the quadrivalent meningococcal vaccine group vs n=52 in the trivalent inactivated influenza vaccine group). In the intention-to-treat population, overall infant vaccine efficacy was 33·1% (95% CI 3·7-53·9); in the per-protocol population, vaccine efficacy was 37·3% (7·6-57·8). Vaccine efficacy remained robust during the first 4 months of follow-up (67·9% [95% CI 35·1-85·3] by intention to treat and 70·2% [35·7-87·6] by per protocol), before diminishing during the fifth month (57·3% [30·6-74·4] and 60·7 [33·8-77·5], respectively). Adverse event rates in women and infants were similar among groups. Pain at the injection site was more common in women given quadrivalent meningococcal vaccine than in those given trivalent inactivated influenza vaccine (n=253 vs n=132; p<0·0001), although 354 [92%] reactions were mild. Obstetrical and non-obstetrical serious adverse events were reported in 60 (3%) women in the quadrivalent meningococcal vaccine group and 61 (3%) women in the trivalent inactivated influenza vaccine group. Presumed neonatal infection was more common in infants in the trivalent inactivated influenza vaccine group than in those in the quadrivalent meningococcal vaccine group (n=60 vs n=37; p=0·02). No serious adverse events were related to vaccination. INTERPRETATION: Vaccination of pregnant women with trivalent inactivated influenza vaccine in Mali-a poorly resourced country with high infant mortality-was technically and logistically feasible and protected infants from laboratory-confirmed influenza for 4 months. With adequate financing to procure the vaccine, implementation will parallel the access to antenatal care and immunisation coverage of pregnant women with tetanus toxoid. FUNDING: Bill & Melinda Gates Foundation.

Overview

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1016/s1473-3099(16)30054-8

Cites

29 of 29 references verified0 citation errors · 0 not checkable

Statistics

Figures

Figure 1 Trial profile TIIV=trivalent inactivated influenza vaccine. MCV=quadrivalent meningococcal conjugate vaccine. *1886 (91%) infants were born to women vaccinated with TIIV 14 or more days prepartum. †1869 (92%) infants were born to women vaccinated with MCV 14 or more days prepartum.
Figure 1 Trial profile TIIV=trivalent inactivated influenza vaccine. MCV=quadrivalent meningococcal conjugate vaccine. *1886 (91%) infants were born to women vaccinated with TIIV 14 or more days prepartum. †1869 (92%) infants were born to women vaccinated with MCV 14 or more days prepartum.CC BY · PubMed Central
Figure 2 Vaccine efficacy and HAI antibody geometric mean titres in infants, by age and maternal vaccine group Error bars and data in parentheses show 95% CIs. TIIV=trivalent inactivated influenza vaccine. MCV=quadrivalent meningococcal conjugate vaccine. HAI=hemagglutination inhibition antibodies.
Figure 2 Vaccine efficacy and HAI antibody geometric mean titres in infants, by age and maternal vaccine group Error bars and data in parentheses show 95% CIs. TIIV=trivalent inactivated influenza vaccine. MCV=quadrivalent meningococcal conjugate vaccine. HAI=hemagglutination inhibition antibodies.CC BY · PubMed Central

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 29 references

Cited by

See all 252

Metadata

Authors
Tapia, M. D., Sow, S. O., Tamboura, B., Tégueté, I., Pasetti, M. F., Kodio, M., Onwuchekwa, U., Tennant, S. M., Blackwelder, W. C., Coulibaly, F., Traoré, A., Keita, A. M., Haidara, F. C., Diallo, F., Doumbia, M., Sanogo, D., DeMatt, E., Schluterman, N. H., Buchwald, A., Kotloff, K. L., Chen, W. H., Orenstein, E. W., Orenstein, L. A. V., Villanueva, J., Bresee, J., Treanor, J., & Levine, M. M.
Affiliations
  • University of Maryland, Baltimore (US)
  • Centre Pour le Développement des Vaccins-Mali (ML)
  • United States Department of Veterans Affairs (US)
  • Children's Hospital of Philadelphia (US)
  • Emory University (US)
  • Centers for Disease Control and Prevention (US)
  • University of Rochester Medicine (US)
Corresponding author
Levine, Myron M
Venue
The Lancet Infectious Diseases
Publisher
Elsevier BV
Published
2016-09
Volume
16
Issue
9
Pages
1026-1035
ISSN
1473-3099 (ISSN-L)
OpenAlex
W2414404462
Cited by
245
References
29
Citations by year
2026: 7 · 2025: 13 · 2024: 15 · 2023: 13 · 2022: 13 · 2021: 27 · 2020: 31 · 2019: 56 · 2018: 30 · 2017: 34 · 2016: 5
FWCI
39.08
Type
journal article
Language
en
Open access
Licence
Locations
  • The Lancet Infectious Diseases (publishedVersion, cc-by)
  • PubMed Central (publishedVersion, cc-by)
  • PubMed (publishedVersion)
Funders
Bill & Melinda Gates Foundation (OPP1002744)
Topics
  • Health Sciences › Medicine › Epidemiology › Influenza Virus Research Studies
  • Health Sciences › Medicine › Epidemiology › Respiratory viral infections research
  • Life Sciences › Immunology and Microbiology › Microbiology › Bacterial Infections and Vaccines
Keywords
maternal immunization, trivalent inactivated influenza vaccine, quadrivalent meningococcal vaccine, vaccine efficacy, vaccine safety, immunogenicity, influenza-like illness, infants under 6 months, Mali, pregnant women, cross-protective immunity, seroconversion, seroconversion rate
MeSH terms
Adjuvants, Immunologic, Adult, Female, Humans, Immunization, Immunization Schedule, Infant, Infant, Newborn, Influenza, Human, Influenza Vaccines, Mali, Prospective Studies, Vaccination, Meningococcal Vaccines

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Maternal immunisation with trivalent inactivated influenza vaccine for prevention of influenza in infants in Mali: a prospective, active-controlled, observer-blind, randomised phase 4 trial. https://app.cochat.ai/papers/10.1016/s1473-3099(16)30054-8
The paper
Tapia, M. D., Sow, S. O., Tamboura, B., Tégueté, I., Pasetti, M. F., Kodio, M., Onwuchekwa, U., Tennant, S. M., Blackwelder, W. C., Coulibaly, F., Traoré, A., Keita, A. M., Haidara, F. C., Diallo, F., Doumbia, M., Sanogo, D., DeMatt, E., Schluterman, N. H., Buchwald, A., . . . Levine, M. M. (2016). Maternal immunisation with trivalent inactivated influenza vaccine for prevention of influenza in infants in Mali: a prospective, active-controlled, observer-blind, randomised phase 4 trial. The Lancet Infectious Diseases. https://doi.org/10.1016/s1473-3099(16)30054-8

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.